In a significant legislative development for the American biomedical research community, Congress has finalized and passed the Department of Health and Human Services (HHS) funding bill for fiscal year (FY) 2026, securing an essential increase in resources for the National Institutes of Health (NIH). The final appropriations package includes an additional $415 million for the NIH, a move that signals a rejection of proposed austerity measures that threatened to destabilize the nation’s scientific infrastructure. Within this allocation, $10 million has been specifically earmarked for diabetes research, a core priority for the Endocrine Society and its global network of researchers and clinicians.
This funding victory follows a period of intense advocacy led by the Endocrine Society and a broad coalition of medical and patient organizations. The legislative outcome is particularly noteworthy given the initial budgetary climate; early proposals from the administration had suggested a drastic 40% reduction in NIH research funding. Such a cut would have resulted in the cancellation of thousands of active grants and a fundamental restructuring of the NIH’s 27 institutes and centers, potentially disrupting decades of progress in endocrine-related scientific inquiry.
Legislative Protections and Budgetary Safeguards
Beyond the raw funding figures, the FY 2026 bill incorporates specific language championed by the Endocrine Society to safeguard the operational integrity of the NIH. These provisions are designed to ensure that funding remains predictable and that the administrative burden on research institutions is minimized.
Key protections included in the legislation address the following areas:
- Limitation of Multi-Year Funding Maneuvers: The bill restricts the use of budget maneuvers that front-load grant funding, a practice that can artificially inflate current spending figures while leaving future years vulnerable to shortfalls.
- Prohibition of Indirect Cost Rate Caps: Congress has prohibited the imposition of arbitrary caps on indirect cost rates. These rates cover essential institutional overhead, such as laboratory maintenance, utilities, and administrative support, which are vital for the execution of high-level research.
- Expedited Grant Payments: To maintain the momentum of clinical trials and laboratory studies, the bill requires that grants be paid within five business days of approval, ensuring that cash flow issues do not stall critical scientific work.
- Reclamation of Congressional Authority: The language reinforces the role of Congress in overseeing federal spending, preventing the executive branch from unilaterally redirecting funds away from congressionally mandated research priorities.
Chronology of the Advocacy Campaign
The path to the FY 2026 funding agreement was the result of a year-long strategic effort. The Endocrine Society utilized a multi-faceted approach to influence policymakers, beginning in early 2025 when the threat of deep cuts first emerged.
In the spring and summer of 2025, the Society initiated a series of online advocacy campaigns, mobilizing thousands of members to contact their representatives. This was followed by "Hill Days," where endocrine researchers and clinicians met directly with congressional staff to explain the real-world impact of NIH-funded research on patient care, particularly in areas like hormone-regulated cancers, obesity, and metabolic disorders.
By late 2025, the Society had successfully convened a massive coalition of over 140 professional medical societies and patient advocacy groups. This unified front culminated in a high-level letter to congressional leadership, which served as a final push during the appropriations negotiations. The breadth of this coalition underscored the universal concern across the medical community regarding the potential dismantling of the NIH’s peer-review and funding systems.
Reauthorization of the Special Diabetes Program and Telehealth Extensions
Simultaneous with the NIH funding debate, the Endocrine Society achieved significant wins in the areas of diabetes care and digital health. In February, the President signed into law a large appropriations package that included the reauthorization of the Special Diabetes Program (SDP) and a two-year extension of Medicare telehealth waivers.
The SDP has been a cornerstone of diabetes research and prevention since its inception in 1997. The new legislation funds the program at $200 million per year, representing a $40 million increase for each of its two primary components. One component, managed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), focuses exclusively on Type 1 diabetes research. The second component supports prevention and treatment programs for indigenous communities, administered through the Indian Health Service (IHS).
The success of the SDP reauthorization was attributed to the bipartisan leadership of the Senate and House Diabetes Caucuses. Senators Susan Collins (R-ME) and Jeanne Shaheen (D-NH), along with Representatives Diana DeGette (D-CO) and Michael Bilirakis (R-FL), were instrumental in navigating the bill through a divided Congress.
Furthermore, the extension of Medicare telehealth waivers through the end of 2027 provides much-needed stability for endocrinologists, who are among the most frequent users of telehealth services within the Medicare system. These waivers allow patients to receive specialized care from their homes, a flexibility that has proven essential for managing chronic conditions that require frequent monitoring, such as diabetes and thyroid disorders.
Congressional Scrutiny and NIH Modernization
While funding has been secured for the immediate future, the structure of the NIH remains a subject of intense debate on Capitol Hill. The Senate Committee on Health, Education, Labor, and Pensions (HELP) recently held a hearing focused on "modernizing" the NIH. This hearing featured testimony from NIH Director Jayanta Bhattacharya, who faced rigorous questioning regarding the agency’s future direction.
Several senators expressed profound concern over the recent history of canceled grants and the potential long-term damage to the biomedical workforce. Senator Susan Collins highlighted how funding instability and cuts to diversity and equity initiatives have disproportionately affected research into women’s health and health disparities. She also noted that the current environment is discouraging early-career scientists from remaining in academia, potentially leading to a "brain drain" in American science.
Senators Lisa Murkowski (R-AK) and Tammy Baldwin (D-WI) raised alarms regarding leadership vacancies at various NIH Institutes and Centers (IC). Baldwin, in particular, pressed Director Bhattacharya on the importance of involving external scientists in the search for new IC directors and questioned the impact of increasing multi-year funding obligations on the agency’s flexibility.
Director Bhattacharya reiterated his commitment to restoring public trust in science and ensuring that the NIH remains focused on the health of the American public. However, his remarks regarding the continuity of care for patients enrolled in canceled clinical trials—stating that such care was the responsibility of individual researchers rather than the NIH—drew sharp reactions from advocates who argue the federal government must provide a safety net for participants in its sponsored studies.
Educational Outreach on GLP-1s and Metabolic Health
The Endocrine Society’s influence has also extended into the realm of clinical education for policymakers. On January 22, the Society partnered with the American Association for the Study of Liver Diseases (AASLD) to host a congressional briefing titled “GLP-1s: A Game Changer for the Treatment of Liver Disease.”
Led by former Endocrine Society President Dale Abel, MD, PhD, the briefing educated congressional staff on the physiological mechanisms of GLP-1 receptor agonists. These medications, originally developed for diabetes, have shown transformative potential in treating obesity and associated conditions like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Dr. Abel’s subsequent meetings with congressional leadership helped establish the Endocrine Society as the authoritative voice on the policy implications of these "blockbuster" drugs, particularly regarding insurance coverage and patient access.
Future Outlook: The FY 2027 Budget Cycle
The victory for FY 2026 provides only a brief respite, as the federal budget cycle for FY 2027 is already underway. The administration is expected to release its new budget proposal in mid-March, and the Endocrine Society anticipates renewed attempts to curtail research spending.
In response, the Society has scheduled a virtual Hill Day for March 13, where members will once again engage with congressional offices to advocate for steady, sustainable funding increases. The organization’s leadership has emphasized that the battle for scientific funding is a perpetual one, requiring constant vigilance and a proactive presence in Washington.
The broader implications of these funding decisions extend beyond the laboratory. As the U.S. faces rising rates of chronic endocrine disorders, the stability of the NIH and programs like the SDP remains critical to national health security. The Endocrine Society’s recent successes demonstrate that a coordinated, data-driven advocacy strategy can effectively counter even the most significant budgetary threats, ensuring that the United States remains at the forefront of medical innovation and patient care.